Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,536 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT03518138 | Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor | completed | Phase 2 | 132 | Que OncologyINDUSTRY | 3 | Jul 23, 2021 |
| clinicaltrials |
| NCT02124772 | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | completed | Phase 1 / Phase 2 | 139 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 14, 2021 | clinicaltrials |
| NCT03451084 | A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia | completed | Phase 2 | 24 | ASLAN PharmaceuticalsOTHER | 3 | Jul 6, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01719380 | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | completed | Phase 2 | 156 | PfizerINDUSTRY | 12 | Jun 23, 2021 | clinicaltrials |
| NCT02435680 | Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)(TNBC) | completed | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT02574637 | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease | terminated | Phase 2 | 29 | AstraZenecaINDUSTRY | 12 | May 26, 2021 | clinicaltrials |
| NCT01403064 | Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects | terminated | Phase 2 | 76 | CSL BehringINDUSTRY | 6 | May 11, 2021 | clinicaltrials |
| NCT02569801 | A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy(HydranGea) | terminated | Phase 2 | 71 | Genentech, Inc.INDUSTRY | 6 | Apr 23, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT03301597 | NLA101 in Adults Receiving High Dose Chemotherapy for AML(LAUNCH) | terminated | Phase 2 | 146 | Nohla Therapeutics, Inc.INDUSTRY | 3 | Mar 30, 2021 | clinicaltrials |
| NCT02750514 | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer(FRACTION-Lung) | terminated | Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 8 | Mar 22, 2021 | clinicaltrials |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants(CheckMate 7UA) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 19, 2021 | clinicaltrials |
| NCT03600467 | Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma(START) | terminated | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT01783444 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.(BOLERO-6) | completed | Phase 2 | 309 | Novartis PharmaceuticalsINDUSTRY | 18 | Feb 26, 2021 | clinicaltrials |
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | terminated | Phase 2 | 317 | Hoffmann-La RocheINDUSTRY | 11 | Feb 3, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | terminated | Phase 2 | 162 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 10 | Jan 22, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT01246986 | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | completed | Phase 2 | 204 | Eli Lilly and CompanyINDUSTRY | 7 | Jan 12, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). | terminated | Phase 2 | 171 | Hoffmann-La RocheINDUSTRY | 11 | Jan 5, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT00885196 | A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis | completed | Phase 2 | 336 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 22, 2020 | clinicaltrials |
| NCT01058434 | Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation | completed | Phase 2 | 43 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT00411528 | Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 185 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01084330 | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | completed | Phase 2 | 68 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 10, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT01781572 | A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | completed | Phase 1 / Phase 2 | 102 | PfizerINDUSTRY | 5 | Dec 7, 2020 | clinicaltrials |
| NCT02610140 | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | completed | Phase 2 | 248 | BayerINDUSTRY | 14 | Nov 4, 2020 | clinicaltrials |
| NCT00723957 | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | completed | Phase 2 | 260 | R-PharmINDUSTRY | 10 | Oct 28, 2020 | clinicaltrials |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Oct 27, 2020 | clinicaltrials |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer(BATON-BC) | terminated | Phase 2 | 30 | AVEO Pharmaceuticals, Inc.INDUSTRY | 10 | Oct 27, 2020 | clinicaltrials |
| NCT01526356 | Topical Rapamycin to Erase Angiofibromas in TSC(Treatment) | completed | Phase 2 | 179 | The University of Texas Health Science Center, HoustonOTHER | 2 | Oct 26, 2020 | clinicaltrials |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label(FOCAL) | terminated | Phase 2 | 10 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 22, 2020 | clinicaltrials |
| NCT00542919 | A Study for Patients With Non-Hodgkin's Lymphomas | completed | Phase 2 | 57 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 7 | Oct 1, 2020 | clinicaltrials |
| NCT02319044 | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 267 | AstraZenecaINDUSTRY | 15 | Sep 29, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials